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Patient registries play an important role in obtaining real-world evidence of the cost-effec-
tiveness of treatments. However, their implementation is costly and sometimes infeasible in
many middle-income countries (MICs). We explored the combination of data-mining and a
large claims database to estimate the direct healthcare costs of HER2-positive breast can-
cer (BC) treatment in Iran and the fraction of total costs from trastuzumab use.
Method
We performed a retrospective analysis of claims data from the Iran Social Security Organi-
zation, a health insurer which covers approximately 50%(~40 million) of the Iranian popula-
tion, in the period of 21/03/2011-20/03/2014. A data-mining algorithm using R software and
validated using patient dossiers in the Cancer Research Center identified 1295 patients and
divided them into the three main HER2-positive breast cancer stages (early, loco-regional
and advanced). A payer perspective was used to calculate the absolute and relative direct
costs of healthcare services associated with the treatment of HER2-positive breast cancer
in the public and private healthcare systems.
Results
The number of women totaled 802 (early), 125 (loco-regional) and 218 (advanced). The
mean age[SD] was 45[10], 46[10] and 48[10] years, respectively, while mean follow-up in all
stages was approximately one year. Average costs of direct healthcare care in early, loco-
regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 (95%CI:
€6,843-€10,002), and €17,742 (95%CI: €15,720-€19,505), respectively. Trastuzumab
accounted for the largest share of total costs in all three stages (range: 53–76%).
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Conclusion
Wherever comprehensive patient registries are infeasible or costly, real-world costs can be
estimated through claims databases and data-mining strategies. Using this method, real-
world costs have been estimated in Iran. The stage-specific cost estimates derived from this
study can be used to perform real-world cost-effectiveness analyses of therapies for HER2-
positive BC and support healthcare financing decisions.
Introduction
Useful cost-effectiveness analyses require sufficiently detailed data on both costs and health
outcomes to support decisions about the reimbursement or implementation of new inter-
ventions [1]. Patient registries are an important source of patient level data that can be used
to estimate the real-world costs and effectiveness of treatments. A good example is the
Swedish National Patient Register which covers more than 99% of hospital services with a
validation rate of 85–95% [2]. However, implementation of patient registries is costly and
sometimes infeasible in many middle-income countries (MICs). Therefore, other strategies
may be needed to obtain the data needed for a cost-effectiveness analysis. Claims databases
are one of the possible sources to obtain valuable data on resource use in MICs. In this
study, we describe how we used a claims database to obtain important stage-specific infor-
mation on breast cancer (BC) in an MIC. Breast cancer was chosen since it is the most fre-
quent cancer in women worldwide with an estimated 1.67 million new cancer cases
diagnosed in 2012 (25% of all cancers)[3–5].
BC has become one of the most frequent malignancies among Iranian women [6], which
has led to increased efforts to reduce its mortality through prevention or treatment. However,
the impact of BC treatment on the overall healthcare budget can be dramatically high because
of the costs of medications such as targeted therapy with monoclonal antibodies (trastuzu-
mab); even though the proportion of BC patients with HER2-positive who need to use trastu-
zumab is approximately 20–25% [7]. To the best of our knowledge, there is no country-
specific cost analysis in Iran that has reported results that can be extrapolated to the general
Iranian population. Therefore, in this study we aimed at exploring how data-mining using a
claims database can yield valuable information (stage-specific resource use and costs related to
different stages of HER2-positive BC) for policymaking and cost-effectiveness analyses. This
aim was achieved by using an example involving trastuzumab.
Methods
General study design
Data from a claims database of the largest health insurance database in Iran were processed
using data-mining, combined with data from other sources, and then analyzed to estimate the
direct healthcare costs of HER2-positive BC in each disease stage from a payer’s perspective.
The results of the data-mining process were verified using patient level-data. To access the
above data sources, a research proposal was sent to the Social Security Organization (SSO) and
the Cancer Research Center (CRC) to obtain claims data and patient-level data, respectively.
After approval, we received the data requested in our proposal. The following sections describe
the main parts of the study. Fig 1 shows an overview of the different steps of the study.
Direct healthcare costs of HER2-positive breast cancer in Iran
PLOS ONE | https://doi.org/10.1371/journal.pone.0205079 October 1, 2018 2 / 16
the data will only be accessible if the committee
approves the application. Data from patients
dossier are available at the Cancer Research Center
(Tehran University for Medical Sciences). The
“Ethical committee” at this university will make a
decision for researchers who meet the criteria for
access to confidential data.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
Data sources for healthcare resource use
Three sources were used to estimate healthcare resource use and costs. To start with, most data
on outpatient services and costs were drawn from a major claims database of the Social Secu-
rity Organization (SSO), a social and health insurance organization that covers more than 50%
(~40 million insurees) of the whole Iranian population [8]. Second, due to the absence of an
integrated country level database, data on inpatient services came from two general referral
hospitals (Fayazbakhsh and Alborz), which operate under the supervision of the SSO [9]. Out-
patient and inpatient data were received anonymously. Lastly, we used the results of a survey
of 52 oncologists [7] to estimate some minor outpatient costs in those rare cases where health
care services were not covered by the SSO (e.g., services provided by doctors in their private
offices). Data from these three sources were combined and analyzed in three general steps.
Step 1: Data-mining (Identification and categorization of patients and
treatment regimens)
This step comprised several sub-steps which are as follows:
Step 1.1: Design of patient classification algorithm. The results of a survey of oncolo-
gists [6] and other sources such as clinical guidelines [1,9,10] were used to design a strategy for
patient classification. The strategy was assessed by two academic oncologists and modified
based on their feedback. The final patient classification algorithm was based on medication
patterns (combination and/or sequence of drug administration) seen between three index
dates.
Fig 1. An overview of the different steps of the study.
https://doi.org/10.1371/journal.pone.0205079.g001
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Step 1.2: Data requirements. Since different types of data were needed to classify patients
and estimate stage-specific costs, we prepared a list of necessary data in each category and then
defined our data extraction strategy.
Step 1.3: Data extraction. Four filters were used to select patients with HER2-positive BC
in the main SSO database: diagnosis of cancer, female, history of a mammography and trastu-
zumab use in the past two years. The Iranian national health services coding system was used
to identify women who underwent a mammography and received trastuzumab. After identify-
ing patients, all cost data associated with BC in various healthcare services (e.g. medication,
diagnosis tests, medical imaging, radiotherapy and hospitalization) were then extracted from
different databases.
Step 1.4: Data cleaning. This step involved a check for duplications, completeness of data,
and consistency of chemotherapy approaches. Any duplicated records were removed from the
database. Then, to improve completeness and uniformity of data, two exclusion criteria were
applied. Firstly, we excluded patients who had too few (n<6) “healthcare request sheets” over a
period longer than two months since the date of the first prescription containing chemotherapy.
It is worth nothing that these healthcare request sheets are used by doctors to prescribe necessary
healthcare services for their patients. The Persian term for these sheets is “nos’kheh”, which we
have translated to “healthcare request sheet” for lack of a better word. Each healthcare request
sheet may contain one or multiple services. This is an instrument to connect doctors, other
health care providers, and payers. We excluded patients with 5 or fewer healthcare request sheets
because they had probably not yet completed the entire treatment regimen (type II right censor-
ing). That is, patients who have completed the entire regimen should have at least six healthcare
request sheets, which would consist of 3–4 healthcare request sheets for chemotherapy, 1–2
sheets for other medications such as hormone therapy, one sheet for laboratory test and one
sheet for medical imaging during first two months of treatment onset. In fact, this threshold of 5
healthcare request sheets lies well below the number of prescriptions associated with an entire
regimen. Secondly, patients were also excluded if they had a treatment regimen that was differ-
ent than our previously defined treatment strategies.
Step 1.5: Applying the classification algorithm. Classification algorithm was used to cat-
egorize patients into three different stages (“early BC”, “loco-regional BC” and “advanced
BC”) based on medication patterns over a 3-year observation period (21.3.2011–20.3.2014). A
decision tree induction using a divide-and-conquer approach [10] was used to predict disease
stages. We also used distance matrix analysis [11,12] to obtain possible medication combina-
tions (Fig 2). In the divide phase, we divided outpatient records into three main groups (radio-
therapy, chemotherapy, and other medications). The main groups were continually divided
into a number of subgroups of the same (or related) type until these subgroups became simple
enough to find possible combinations by using distance matrix analysis. Then, in the conquer
phase we found possible combinations of medication and radiotherapy over the observation
period. Based on the results of the survey and guidelines we combined these different combi-
nations to find the possible medication patterns. Afterwards, we calculated the probability that
a particular woman had early BC, loco-regional BC or advanced BC. The probability that a
woman was in a given health state was based on the ‘confidence’ about the association between
our previously defined patterns and discovered patterns. Therefore, the confidence was calcu-
lated by dividing the number of discovered medication patterns representing any specific
health state by the number of all discovered medication patterns in all health states [11]. For
example, if we discovered three medication patterns in a patient’s profile, the value of confi-
dence to classify that patient as being in early BC would be 33.3% (100%/3), if one of the three
discovered medication patterns was only seen in early BC cases and the two other patterns in
later-stage BC cases. We also defined a minimum threshold of 70% for stage-specific
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confidence. If the confidence of one of the three stages was higher than 70%, the patient was
categorized into that stage. Otherwise, we examined the possibility of overlap between the
groups. In other words, the possibility that patients progressed (e.g. from early BC to loco-
regional or advanced BC) during the observation period. In this case, we looked at the differ-
ence between index dates of each health state. If the difference between two or three index
dates was more than 3 months, patients were categorized into multiple stages with different
index dates, otherwise the health state with the highest confidence was selected. Based on the
results of a clinician survey [7], the index date for each patient with early BC was based on the
first date of chemotherapy or radiotherapy (whichever happened earlier) according to possible
drug combinations for early BC treatment. The loco-regional BC index date was defined as the
first date when the patient received vinorelbine or capecitabine use or single-agent chemother-
apy by taxols (docetaxel or paclitaxel). Finally, the index date for advanced BC patients was the
first date of gemcitabine, zoledronic acid or temozolomide use. Patients who could not be clas-
sified into one of the three stages due to lack of chemotherapy records were categorized as
unclassifiable.
In general, data-mining resulted in the classification of patients into three health states,
including a patient-specific time interval representing the start and end dates of treatments at
any particular health state.
Step 2: Verification of patient classification algorithm
Patient-level data from the CRC were used to verify the results of the patient classification
algorithm. In total, there were 51 patients at this center who were HER2-positive and SSO ben-
eficiaries; HER2-positive BC was based on whether an IHC result showed two or more pluses
or the FISH test was positive. Verification involved comparing the results of the algorithm
results with the clinical results based on the tumor, node, and metastases (TNM) classification
system. We examined if patients categorized as having early stage BC by the classification algo-
rithm were in stages I or II of BC, if patients with loco-regional BC had stage III BC and if
patients with advanced BC had stage IV BC. The SSO’s ID of patients in the CRC were used to
link this small dataset to the claims database by SSO’s database management staff. The result of
any patient classification by data-mining was approved (based on expert opinion), firstly, if the
same stage had been reported in the patient dossier. Secondly, if the stage-specific index date
obtained from data-mining was within two months greater than the stage-specific diagnosis
date in the patient dossier.
Fig 2. The processes of patient classification.
https://doi.org/10.1371/journal.pone.0205079.g002
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Step 3: Cost calculations
A national coding system covers both inpatient and outpatient healthcare services in Iran.
Each healthcare service (e.g. a tablet of acetaminophen or open-heart operation) has a unique
code. The national coding system is developed by the Ministry of Health. Healthcare providers
must use this system (drugs + other services) when they seek payment for the procedures and
services they have provided to individual patients. Healthcare providers send a text file includ-
ing the patient’s ID, national codes of all services used for that patient, doctor’s ID and costs
(co-payments plus payers’ share costs) to the SSO (i.e., the health insurer), either daily or
monthly. Ultimately, knowing the code of any services make it possible to identify users, pre-
scribers and the costs of that particular healthcare service.
Considering the above information, firstly, ‘service-specific costs’ were estimated using the
national coding system. Outpatient care costs were calculated based on prevalent healthcare
services (e.g. chemotherapy, hormone therapy, radiotherapy, diagnostic tests and medical
imaging). Inpatient costs were estimated by extracting data from two hospitals on the surgical
procedures used in BC management (e.g., lumpectomy, mastectomy and oophorectomy); this
data were extracted from the same period as the outpatient data (21.3.2011–20.3.2014).
Afterwards, we used the results of data-mining to calculate ‘stage-specific costs’. As men-
tioned earlier, data-mining was used to categorize patients into three health states. Moreover,
data-mining helped us to determine the duration of time that individual patients spent in each
health state (stage-specific time interval). Therefore, stage-specific costs over time were esti-
mated as follows. Costs of various outpatient services (e.g. medications, radiotherapy, diagnos-
tic tests, medical imaging) were calculated based on the individual stage-specific time interval.
For those patients whose outpatient and inpatient data were available, inpatient costs were cat-
egorized based on their stage-specific time interval obtained from data-mining on outpatient
data.
In both service- and stage-specific costs, we also included treatment costs in the private sec-
tor, since the unit costs can differ between the public and private sector and patients are free to
choose their healthcare provider [9,13]. Therefore, to estimate the treatment costs of patients
in the private sector, the prices of healthcare services in the public sector were first converted
to private prices based on the official private tariffs in the period of 2011–2014 [14,15]. Treat-
ment costs in the private sector were then calculated based on resource use and converted
prices. In certain rare instances, this conversion was also based on the results of a survey of Ira-
nian oncologists [7]. In all above steps, costs unassociated with BC as well as the costs of
uncompleted treatment regimens were excluded from the analysis.
Analysis
The claims data were analyzed to determine the mean and distribution of resource use and
costs of different medical treatment regimens, including chemotherapy, hormone therapy,
radiotherapy, laboratory tests, medical imaging services and surgery in the different BC stages.
95% confidence intervals (CIs) were calculated using non-parametric bootstrapping. The
number of iterations was 2000 times in all cases. All data-mining process and calculations
were made using R software (version 3.2.2) for Windows [16].
Results
Data extraction, cleaning and patient classification
The data extraction process yielded 1,295 patients with an average age [SD] of 44 [10] years
(Table 1). 54 patients were excluded from the study due to small number of prescriptions or
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inconsistency between their chemotherapy approach and our previously defined drug combi-
nations. Of the 1,241 patients, 802, 125 and 218 patients were categorized into early BC, loco-
regional BC and advanced BC, respectively during a mean [SD] follow-up period of 679 [289]
days. The mean ages of women in the different health stages ranged from 45–48 years and
average follow-up durations per patient [SD] was 425 [210] days. Furthermore, on average, the
mean follow-up durations per stage [SD] were 397 [198] (early BC), 349 [234] (loco-regional
BC) and 318 [204] (advanced BC) days. During the follow-up period, 158 patients with early
BC progressed to loco-regional BC (n = 41) or advanced BC (n = 106), 19 patients progressed
from loco-regional BC to advanced BC, and 11 patients progressed through all three BC stages.
Finally, 284 patients were not classifiable due to lack of chemotherapy records.
Patient classification verification
Verification of patient classification was based on data obtained from CRC on a group of 51
patients; 65% (n = 33) were in early BC, 10%(n = 5) in loco-regional BC and 25%(n = 13) in
advanced BC. Two (4%) patients had both loco-regional and advanced BC in the observation
period. Some patients with loco-regional and advanced BC were incorrectly categorized as
having early stage BC; these represented 14% (n = 7) of patients in the loco-regional stage and
2% (n = 1) of patients with advanced BC). Therefore, the accuracy by stage was 100% (25/25)
for early BC, 46% (6/13) for loco-regional BC and 93% (14/15) for advanced BC. In general,
verification of the classifications based on data-mining revealed an 85% accuracy rate.
Service-specific costs—Outpatient costs
The different outpatient costs are shown in Table 2. The costs were weighted based on pro-
portion of resource use between public and private sectors; medication costs required no
weighting because there are no price differences between the two sectors. The costs also
included the costs of drugs used as concomitant drugs like antiemetics. The most common
chemotherapy regimen among early BC patients consisted of a taxane (docetaxel or pacli-
taxel) along with doxorubicin and cyclophosphamide (66%). The more expensive medica-
tions in early BC comprised different combinations of chemotherapy including docetaxel.
Patients with loco-regional BC were almost evenly distributed among different treatment
regimens. Vinorelbine was used in the treatment of almost half (45%) of the advanced BC
patients. Tamoxifen and letrozole were the two most common types of hormone therapy.
Table 1. Age characteristics of study patients with HER2-positive BC.
Stages Before analysis Early BC Loco-regional BC Advanced BC
Number of patients 1295 802 125 218
Age at start date (2011-03-21) at index date at index date at index date
Average [SD] 44 [10] 45 [10] 46 [10] 48 [10]
Age range (%)
34 222 (17) 120 (15) 15 (12) 21 (10)
35–44 447 (35) 261 (33) 46 (37) 54 (25)
45–54 409 (32) 267 (33) 38 (30) 84 (39)
55–64 172 (13) 124 (15) 22 (18) 47 (22)
65 45 (3) 30 (4) 4 (3) 12 (6)
Abbreviations: BC: Breast cancer; SD: Standard deviation.
https://doi.org/10.1371/journal.pone.0205079.t001
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Table 2. Average costs of outpatient services.
Costs as of 20.03.2014 (1€ = 34,000 rials) Provided in the public sector n = 1,241
Treated (%) Mean [SD] € Range €
Medications
Chemotherapy (Early BC)
All NA 802 (65) 11,865 [8,247] 623–45,275
trastuzumab NA 757 (61) 10,565 [7,668] 332–40,447
doxorubicin + cyclophosphamide + docetaxel NA 314 (25) 2,480 [1,335] 105–6,925
doxorubicin + cyclophosphamide + paclitaxel NA 236 (23) 1,164 [433] 249–2,444
epirubicin + cyclophosphamide + docetaxel NA 100 (8) 2,507 [1,16] 703–5,459
fluorouracil + epirubicin + cyclophosphamide + docetaxel NA 65 (5) 2,108 [988] 372–4,737
epirubicin + cyclophosphamide + paclitaxel NA 39 (3) 1,321 [390] 638–2,249
fluorouracil + doxorubicin + cyclophosphamide + docetaxel NA 19 (2) 1,747 [802] 713–3,474
paclitaxel OR docetaxel + carboplatin NA 14 (1) 1,953 [1,081] 297–3,721
fluorouracil + epirubicin + cyclophosphamide + paclitaxel NA 12 (1) 940 [235] 604–1,337
fluorouracil + doxorubicin + cyclophosphamide + paclitaxel NA 7 (1) 1,293 [560] 402–2,196
Chemotherapy (Loco-regional BC)
All NA 125 (10) 7,776 75–34,363
trastuzumab NA 90 (9) 8,346 820–29,700
capecitabine NA 42 (3) 604 140–2,165
vinorelbine NA 26 (3) 1,129 26–4,929
paclitaxel NA 19 (2) 750 188–2,846
paclitaxel OR docetaxel + capecitabine NA 18 (2) 1,881 151–4,884
docetaxel NA 18 (2) 1,741 392–3,697
paclitaxel OR docetaxel + carboplatin NA 5 (0) 1,597 446–4,047
Chemotherapy (Advanced BC)
All NA 218 (18) 14,191 [12,045] 108–49,453
trastuzumab NA 198 (16) 11,471 [8,793] 756–42,560
vinorelbine NA 72 (6) 1,967 [1,769] 41–8,845
capecitabine NA 63 (5) 1,277 [845] 159–3,579
paclitaxel OR docetaxel + carboplatin NA 15 (1) 1,672 [1,380] 236–5,627
paclitaxel OR docetaxel + capecitabine NA 29 (2) 1,347 [1,080] 93–2,665
docetaxel NA 16 (1) 1,039 [830] 265–2,690
paclitaxel NA 13 (1) 2,021 [1,918] 155–6,217
doxorubicin + cyclophosphamide + docetaxel NA 3 (0) 1,656 [839] 693–2,227
doxorubicin + cyclophosphamide + paclitaxel NA 3 (0) 1,207 [685] 542–1,910
fluorouracil + epirubicin + cyclophosphamide + paclitaxel NA 3 (0) 1,839 [640] 1,223–2,501
epirubicin + cyclophosphamide + docetaxel NA 1 (0) 713 [NA] 713–713
fluorouracil + epirubicin + cyclophosphamide + docetaxel NA 1 (0) 1,683 [NA] 1,683–1,683
fluorouracil + doxorubicin + cyclophosphamide + paclitaxel NA 1 (0) 2,529 [NA] 2,529–2,529
epirubicin + cyclophosphamide + paclitaxel NA 0 (0) 0 0–0
fluorouracil + doxorubicin + cyclophosphamide + docetaxel NA 0 (0) 0 0–0
lapatinib + capecitabine NA 0 (0) 0 0–0
Hormone therapy
All NA 662 (53) 168 [241] 1–1,257
tamoxifen NA 272 (22) 11 [8] 0–42
tamoxifen + triptorelin NA 135 (11) 407 [245] 51–1,145
letrozole NA 115 (9) 67 [48] 8–327
triptorelin NA 56 (5) 259 [206] 41–812
(Continued)
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In all three BC stages, there is a rapid increase in outpatient-related costs during the first
year after the index date (Fig 3), followed by a gradual increase and a plateau.
Table 2. (Continued)
Costs as of 20.03.2014 (1€ = 34,000 rials) Provided in the public sector n = 1,241
Treated (%) Mean [SD] € Range €
tamoxifen + letrozole + triptorelin NA 27 (2) 475 [329] 69–1,257
tamoxifen + letrozole NA 26 (2) 75 [44] 22–169
exemestan NA 9 (1) 436 [178] 164–777
letrozole + triptorelin NA 7 (1) 553 [356] 229–1,187
tamoxifen + exemestan NA 2 (0) 553 [232] 389–717
goserelin NA 0 (0) 0 0–0
Visit and administration
Oncologist visits per session 0.54# 1,241 (100) 4+ [2] 2Y-7 Y
Chemotherapy administration per session 0.61# 1,241 (100) 28# [23] 4#-103#
Cardiac monitoring services
Cardiac drugs NA 676 (55) 8 [15] 1–156
Internist or Cardiologist visits 0.45 715 (70) 16 [21] 3–206
Cardiology services 0.63 115 (9) 518 [457] 136–1,989
Radiotherapy 0.31 231 (19) 2,426 [1,313] 110–8,530
Laboratory tests
All 0.21 1,180 (97) 112 [88] 2–1,308
Sampling fees 0.26 1,151 (93) 5 [4] 0–33
Hematology 0.25 1,129 (91) 10 [7] 1–50
Clinical chemistry 0.23 1,060 (85) 24 [24] 1–226
Cytopathology 0.19 786 (63) 6 [8] 2–56
Descriptive pathology 0.19 741 (60) 53 [34] 5–352
Tumor marker 0.16 693 (56) 32 [28] 0–263
Urinalysis 0.22 582 (47) 1 [1] 0–13
Hormones 0.15 549 (44) 13 [12] 3–105
Serology and immunology 0.17 403 (32) 10 [15] 1–208
Microbiology 0.27 332 (27) 2 [2] 0–24
Specific clinical chemistry 0.17 320 (26) 8 [6] 1–43
Coagulation 0.17 241 (19) 3 [3] 1–36
Cytogenetics 0.17 24 (2) 162 [114] 2–400
Molecular genetics 0.06 21 (2) 87 [244] 16–1,140
Medical imaging
All 0.19 1,157(93) 612 [1,158] 3–8,697
Ultrasound 0.14 833 (67) 29 [26] 4–197
X-ray 0.22 787 (63) 25 [18] 3–115
CT Scan 0.24 666 (54) 73 [58] 12–443
Nuclear medicine 0.15 476 (38) 73 [66] 15–1,347
MRI 0.22 313 (25) 80 [67] 30–715
Other services 0.25 26 (2) 83 [27] 21–115
Abbreviations: BC: Breast cancer; NA: Not applicable; SD: Standard deviation
 This column shows the proportions of healthcare utilization in the public sector. (Number of services in public sector/Total number of services (private + public).
# The data obtained from the results of a questionnaire survey. [7]
Y The unit costs obtained from the national health care services tariff 2014 [15]
+ The unit cost obtained from the SSO yearly report (2014) [13]
https://doi.org/10.1371/journal.pone.0205079.t002
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Service-specific costs—Inpatient costs
Table 3 shows the inpatient costs based on the two main surgical operations (mastectomy and
oophorectomy), which were based on information from two hospitals and 710 patients during
a 3-year follow-up period (21.3.2011–20.3.2014). The mean costs were calculated using all
components of hospitalization costs, including procedure, nursing, accommodation, medica-
tion, laboratory tests, medical imaging, pathology, medical equipment and physiotherapy. The
Fig 3. Cumulative outpatient main healthcare care costs since the index dates in different health states of
HER2-positive breast cancer in Iran, during a 3-year follow-up period (21.3.2011–20.3.2014).
https://doi.org/10.1371/journal.pone.0205079.g003
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mean [SD] costs of mastectomy and oophorectomy were 293 [178] and 261 [172] euros,
respectively.
Stage-specific direct healthcare costs
As Table 4 shows, trastuzumab accounted for the largest share of total direct healthcare costs;
its share was almost 76% for early BC, 73% for loco-regional BC and 56% for advanced BC.
The relative costs of other medications (including chemotherapy, cardiovascular drugs, anal-
gesics and hormone therapies) were similar in early BC and loco-regional BC but much greater
in advanced BC (Fig 3). Other cost components comprised a limited share of the total costs.
For inpatient services, we found 12 patients who were included in both the outpatient and
inpatient data. Nine of them underwent surgery during early stage BC while the others were
treated during advanced BC, according to the date of surgery (Table 4).
The average cumulative direct healthcare costs for early BC over the follow-up period were
€11,796 (95% CI: €9,356-€12,498). The treatment costs for loco-regional BC averaged €8,253
(95%CI: €6,843-€10,002). In contrast, the mean costs for advanced BC (95% CI) were €17,742
(€15,720-€19,505), which was roughly 50% higher than the costs for early stage BC.
Discussion
Generally, BC is a costly illness throughout the world. The use of monoclonal antibodies like
trastuzumab or pertuzumab to treat BC can have a significant budget impact, specifically in
MICs. We performed a real-world cost analysis using a large claims database and a validated
patient classification algorithm to estimate the stage-specific healthcare utilization and costs
associated with HER2-positive BC in Iran.
Our findings show that total direct healthcare costs per patient averaged €11,796 for early
BC, €8,253 for loco-regional BC and €17,742 for advanced BC during a 3-year follow-up period
(21.3.2011–20.3.2014). The largest share of the total cost was spent on trastuzumab. Other medi-
cations like chemotherapy and hormone therapy were the second most important cost drivers
in BC. The relative costs of other medications associated with advanced BC were dramatically
higher compared with early and loco-regional BC (Fig 3). This was due to the use of other
expensive medications to manage the effects of cancer metastasis to other organs or other medi-
cations to control the side-effects of chemotherapy. In early BC, the most common regimens of
chemotherapy were the combination of an anthracycline antibiotic like doxorubicin and
Table 3. Average costs of mastectomy and oophorectomy. (Costs as of 20.03.2014; 1€ = 34,000 rials).
Inpatient services Number of patients Mean admission days Mean cost € Range €
Mastectomy 141 3.57 [3.09] 293 [178] 31–1,242
Partial 42 1.93 [1.47] 125 [138] 38–718
Partial with axillary lymphadenectomy 7 3.29 [1.11] 179 [63] 103–254
Simple, complete 20 1.60 [1.43] 103 [65] 53–350
Radical, including pectoral muscles and axillary lymph nodes 7 4.57 [3.26] 190 [90] 68–324
Radical, including internal mammary lymph nodes, unilateral 41 5.49 [3.52] 261 [174] 111–1,144
Modified radical, including axillary lymph nodes but leaving pectoral muscles 24 4.63 [2.90] 309 [247] 31–1,242
Oophorectomy 569 3.38 [4.68] 261 [172] 62–2,550
Partial resection of ovary (unilateral or bilateral) 145 3.60 [3.62] 161 [102] 62–756
Wedge resection or bisection of ovary (unilateral or bilateral) 14 6.14 [7.90] 209 [111] 113–547
Ovarian cystectomy (unilateral or bilateral) 374 3.24 [4.83] 200 [196] 66–2,550
Oophorectomy, Unilateral or bilateral, partial or total 36 2.92 [1.42] 166 [104] 83–570
https://doi.org/10.1371/journal.pone.0205079.t003
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cyclophosphamide followed by a taxane-like docetaxel. This corresponds with the results of a
previous study [7]. In contrast to outpatient services, inpatient healthcare cares had only a
minor impact on total costs. It should be noted that BC treatment in Iran is mostly provided on
an outpatient basis, something that has been reported in studies in other countries [17]. For
example, Vera-Lionch et al showed that inpatient costs of BC care, even for metastatic BC,
accounted for approximately 20% of total BC costs in the United States [17]. Another observa-
tion is that our results showed that the average age of BC is lower than the average age seen in
other countries (Table 1). Fifty years was considered as the average age for early HER2-positive
BC based on the majority of trials [18–20]. These results also correspond with the findings of
previous Iranian epidemiological studies [21,22].
A previous study estimated the direct costs of treating patients with BC based on patients
referred to one hospital in Iran [23]. Although that study examined the costs (US$) in different
disease stages over a five-year period (2005–2010) (Stage I: (public: 4,386; private: 8,467), Stage
II: (public: 4,692; private: 8,704), Stage III: (public: 6,845; private: 10,886), Stage IV: (public:
8,077; private: 8,935)) [23], its study population was small, which limited the precision of the
results, and only one hospital was included, which limited the generalizability of the findings.
In addition, that study did not report the costs of patient subgroups with tumor receptor
expression. In contrast, our study provides more details concerning different treatment pat-
terns and cost components on a national level, although it focused only on HER2-positive BC.
Table 4. The overall average costs (public and private sectors) in three stages of BC during the follow-up period. Results after applying nonparametric bootstrapping.
Costs as of 20.03.2014 (1€ = 34,000 rials).
Early BC Loco-regional BC Advanced BC
Number of patients 802 125 218
Average follow up period (Days [SD]) 397 [198] 349 [234] 318 [204]
Provided in the public sector Mean € (SE) Mean € (SE) Mean € (SE)
95%CI 95%CI 95%CI
Trastuzumab NA 9,018 (233) 6,009 (591) 12,985 (648)
8,566–9,452 4,975–7,296 11,745–14,340
Medications (Others) NA 1,838 (44) 1,642 (125) 3,547 (127)
1,764–1,944 1,422–1,906 3,274–3,858
Specialists visit 0.54 79 (4) 86 (7) 119 (11)
76–82 74–98 107–132
Chemotherapy administration# 0.61 135 (46) 145 (42) 220 (16)
122–149 129–161 201–239
Radiotherapy 0.46 440 (32) 243 (61) 121 (48)
382–507 137–385 57–298
Laboratory tests 0.16 57 (2) 51 (6) 54 (5)
54–61 42–65 46–64
Medical imaging 0.24 55 (2) 77 (7) 91 (10)
51–60 64–91 75–118
Inpatient services 0.83 174 (49) - 335 (102)
105–243 215–456
Total (95%CI) 11,796 8,253 17,742
9,356–12,498 6,843–10,002 15,720–19,505
Abbreviations: BC: Breast cancer; CI: Confidence interval; NA: Not applicable; SD: Standard deviation; SE: Standard error
 This column shows the proportions of healthcare utilization in the public sector. (Number of services in public sector/Total number of services (private + public).
# The data obtained from the questionnaire [7]
https://doi.org/10.1371/journal.pone.0205079.t004
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Another recently published study of the economic burden of BC in Iran estimated the overall
direct healthcare costs of BC (US$175,832,701) using a societal perspective [24]. However,
comparisons between their results and our results are not possible since the authors did not
report individual direct healthcare costs for HER2-positive BC.
Like any study, our study also has its limitations. The first limitation relates to our study
population. One could argue that the claim data covers approximately 50% of the population
and therefore may not represent the whole Iranian population. However, our results can be
generalizable to the whole population because the four main payers in Iran have the same ben-
efit package and because the SSO, which provided the data used in our study, covers the insur-
ees from different socio-economic classes in all provinces [6]. A second possible limitation is
that focusing on BC patients treated with trastuzumab may mean that the costs we found are
not generalizable to the costs for other BC patients. While this is certainly true for trastuzumab
costs, this selection is likely to have only a limited effect on other costs since trastuzumab use
does not affect the choice of drug combinations or decisions about dose adjustment of chemo-
therapy [25,26]. Therefore, our results can reflect direct healthcare costs in both patient popu-
lations by including or excluding the costs associated with trastuzumab. Thirdly, since the SSO
database did not include inpatient data, we collected inpatient data from two hospitals, which
means that our cost estimates of inpatient care might not reflect the average costs across all
hospitals in Iran. However, this limitation has no major impact on the overall results since BC
management is mainly performed on an outpatient basis in Iran and the outpatient costs were
based on data from more than 45,700 (~100%) healthcare providers [13]. Fourthly, while data-
mining achieved a high accuracy rate of 85% (of classifying patients into the correct stage of
BC), it was not perfect, meaning that some patients were incorrectly classified. Cost estimates
using the verification results led to an increase in total costs for loco-regional BC (i.e., €10,161,
23% higher than the €8,253 from data-mining) and a slight decrease in total costs for advanced
BC (i.e., €17,402, 2% lower than the €17,742 from data-mining), respectively. Therefore, total
costs in loco-regional BC should be used with caution. The accuracy of classification could be
improved by adding electronic results of diagnostic tests to the patient classification algorithm,
if the results were available. Fifthly, since the patient population and treatment practice at the
center used to validate our data-mining algorithm may be different than patients and treat-
ments elsewhere, it is possible that the true accuracy may be different from the estimated accu-
racy. Finally, the cost estimates in our study do not include illegal and informal payments [27]
by patients to healthcare providers. Authorities in the Ministry of Health currently claim that
they were able to reduce improper payments significantly over the past three years as a result
of president Rouhani’s healthcare reform implementation [28]. However, due to lack of infor-
mation we were not able to determine its impact on the final results of this study. The impor-
tance of excluding these costs may not be significant if the perspective of the healthcare sector
is taken when estimating costs but could be significant if a societal perspective is taken.
This study shows that if relevant data are available, data-mining techniques on claims data
can provide cost estimates that are invaluable in performing real-world cost-effectiveness anal-
yses in MICs. National level cost-effectiveness analyses can use these cost estimates to assess
whether new medicines or procedures are cost-effective. For example, policymakers can
reduce uncertainties about the cost-effectiveness of a monoclonal antibody like trastuzumab
by performing a country-specific cost-effectiveness analysis using the results of our real-world
cost analysis. Despite the advantages of using claims databases, these data sources usually do
not provide clinical, laboratory, and imaging data as well as some important treatment events
such drug-related adverse events.
The quality of reimbursement decision-making can be improved by using information
about actual healthcare utilization and costs. One option in high-income countries would be
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an extensive cost analysis supported by patient registry data and electronic health records.
However, implementation of comprehensive patient registries is costly and sometimes logisti-
cally infeasible in many MICs. If integrated electronic records are unavailable, researchers may
have to rely on small sample sizes or expert opinion (e.g., [23], [24]) to estimate the direct
healthcare costs of an illness. Both of these methods have their shortcomings, which might
affect the internal validity and generalizability of the results. Claims databases would be useful
sources for cost analyses in MICs as long as the disease status of patients is known or ade-
quately predicted.
Conclusion
This study estimated the stage-specific direct healthcare costs associated with HER2-positive
BC in Iran using a large claims database and data-mining with validated patient classification
algorithms. The findings show that the largest component in overall costs in all stages of BC is
medication and that trastuzumab is the major cost driver. These real-world data can support
cost-effectiveness analyses of implementing new technologies for HER2-positive BC manage-
ment and thereby help to optimize reimbursement decision-making in an MIC.
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